tiprankstipranks
ZyVersa Therapeutics (ZVSA)
NASDAQ:ZVSA
US Market

ZyVersa Therapeutics (ZVSA) Income Statement

120 Followers

ZyVersa Therapeutics Income Statement

Last quarter (Q4 2023), ZyVersa Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, ZyVersa Therapeutics's net income was $-13.34M. See ZyVersa Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21
Total Revenue
----
Cost of Revenue
----
Gross Profit
----
Operating Expense
$ 107.75M$ 107.75M$ 820.07K$ -4.25M
Operating Income
$ -107.75M$ -107.75M$ -820.07K$ 4.25M
Net Non Operating Interest Income Expense
$ 457.00$ 457.00--
Other Income Expense
$ 81.40M$ 81.40M-$ -228.10K
Pretax Income
$ -107.75M$ -107.75M$ -820.07K$ 228.10K
Tax Provision
$ -9.46M$ -9.46M$ -745.05K-
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -97.06M$ -106.25M$ -75.02K$ 228.10K
Basic EPS
$ 71.91$ -108.97$ -0.01-
Diluted EPS
$ 71.91$ -108.97$ -0.01-
Basic Average Shares
$ 60.21M$ 975.03K$ 9.02M-
Diluted Average Shares
$ 60.21M$ 975.03K$ 9.02M-
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 107.75M$ 107.75M$ 820.07K$ 4.25M
Net Income From Continuing And Discontinued Operation
$ -98.30M$ -98.30M$ -75.02K$ 228.10K
Normalized Income
$ -27.45M$ -23.91M--
Interest Expense
----
EBIT
$ -86.41M$ -14.42M$ -820.07K$ -240.70K
EBITDA
$ -86.40M$ -14.41M$ -819.54K$ -240.70K
Currency in USD

ZyVersa Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis